Key Points
- CEO Benjamin Palleiko sold 10,034 shares on Feb. 23 at an average price of $15.57 for $156,229, leaving him with 442,883 shares and a 2.22% reduction in ownership.
- Stock snapshot: KALV trades near $15.77 with a market cap of about $797M, a 12‑month range of $9.23–$19.00, a negative PE (‑3.99), and strong liquidity ratios (quick ratio 7.21, current ratio 7.22).
- Market sentiment: Institutions have been accumulating (notably Vestal Point and new stakes like Squadron Capital) and analysts are mostly bullish—seven Buy ratings vs. one Sell—with a consensus price target of $29.40.
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) CFO Brian Piekos sold 1,767 shares of the stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $15.57, for a total value of $27,512.19. Following the transaction, the chief financial officer owned 13,762 shares of the company's stock, valued at approximately $214,274.34. This trade represents a 11.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
KalVista Pharmaceuticals Stock Up 1.3%
Shares of NASDAQ:KALV opened at $15.77 on Wednesday. The firm has a market cap of $797.17 million, a PE ratio of -3.99 and a beta of -0.19. The company has a fifty day simple moving average of $15.47 and a 200 day simple moving average of $13.94. The company has a current ratio of 7.22, a quick ratio of 7.21 and a debt-to-equity ratio of 8.18. KalVista Pharmaceuticals, Inc. has a 12-month low of $9.23 and a 12-month high of $19.00.
Trending Headlines about KalVista Pharmaceuticals
Here are the key news stories impacting KalVista Pharmaceuticals this week:
- Positive Sentiment: Analyst upgrades and higher price targets — Multiple analysts have raised targets and reiterated buy ratings (HC Wainwright to $37, Needham to $32, TD Cowen buy), leaving a consensus target (~$29.40) well above the current price; this analyst optimism supports upside expectations. MarketBeat Analyst Coverage
- Positive Sentiment: Institutional buying — Recent 4Q moves show large new or increased stakes (Vestal Point, Invesco, Squadron Capital among buyers), signalling conviction from professional investors that may underpin the rally. MarketBeat Institutional Activity
- Neutral Sentiment: Speculative price-target article — A Zacks piece highlights a consensus-implied ~117% upside, but frames that as speculative and dependent on future earnings revisions; useful for sentiment but not a catalyst by itself. Zacks Upside Analysis
- Negative Sentiment: Insider selling by multiple executives — CEO Benjamin Palleiko sold 10,034 shares (~2.2% of his stake); CFO Brian Piekos, Nicole Sweeny and Paul Audhya also sold shares on Feb. 23. Concentrated insider sales can be viewed negatively by investors even if for diversification or tax reasons. InsiderTrades: Insider Sales
Institutional Trading of KalVista Pharmaceuticals
Institutional investors and hedge funds have recently made changes to their positions in the stock. BNP Paribas Financial Markets boosted its position in KalVista Pharmaceuticals by 47.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company's stock valued at $46,000 after purchasing an additional 1,292 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in KalVista Pharmaceuticals in the third quarter valued at $55,000. Wolverine Asset Management LLC acquired a new position in shares of KalVista Pharmaceuticals during the third quarter valued at $57,000. KLP Kapitalforvaltning AS bought a new position in shares of KalVista Pharmaceuticals during the third quarter worth about $63,000. Finally, Truvestments Capital LLC grew its position in shares of KalVista Pharmaceuticals by 253.8% during the fourth quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company's stock worth $76,000 after acquiring an additional 3,360 shares during the last quarter.
Wall Street Analysts Forecast Growth
Several equities analysts have recently commented on KALV shares. Citigroup reaffirmed a "market outperform" rating on shares of KalVista Pharmaceuticals in a research report on Tuesday, November 11th. Needham & Company LLC increased their target price on KalVista Pharmaceuticals from $28.00 to $32.00 and gave the stock a "buy" rating in a report on Tuesday, January 6th. TD Cowen reiterated a "buy" rating on shares of KalVista Pharmaceuticals in a report on Wednesday, December 3rd. Weiss Ratings reissued a "sell (d-)" rating on shares of KalVista Pharmaceuticals in a research report on Thursday, January 22nd. Finally, Citizens Jmp decreased their price objective on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a "market outperform" rating for the company in a report on Tuesday, November 11th. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, KalVista Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $29.40.
Check Out Our Latest Stock Report on KALV
KalVista Pharmaceuticals Company Profile
(
Get Free Report)
KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm's scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista's approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.
The company's lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
